Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance

Reuters11-07

Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance

Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581787048?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581787048","market":"us","top_or_hot":-1,"title":"Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4082","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1Fnfd4:1","article_id":"2581787048","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581787048","pubTimestamp":1762464249,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4082":"医疗保健设备","BK4539":"次新股","SGHT":"Sight Sciences, Inc."},"translate_title":"Sight Sciences公布第三季度净亏损820万美元，营收1990万美元，并上调2025年指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGHT":0.9},"content_text":"Sight Sciences posts Q3 net loss of $8.2 million on $19.9 million revenue and raises 2025 guidance\n    \n\n        Sight Sciences Inc. reported third quarter 2025 total revenue of $19.9 million, a decrease of 1.0% compared to the same period in the prior year. The company's Surgical Glaucoma revenue increased 6.0%, while revenue from the Dry Eye segment declined 88.0% compared to the third quarter of 2024, due to a continued focus on achieving reimbursed market access. Net loss for the quarter was $8.2 million, or $0.16 per share, compared to a net loss of $11.1 million, or $0.22 per share, in the prior year period. Total operating expenses were reduced to $25.1 million, down 11.0% year-over-year, including $2.8 million in restructuring costs. Sight Sciences raised its full year 2025 revenue guidance to $76.0 million to $78.0 million, now expecting a 2.0% to 5.0% decline compared to 2024 revenue. Cash and cash equivalents totaled $92.4 million as of September 30, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sight Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-269525), on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581787048","isCrawlerRequest":true}